2 unknown. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 1 | 1 | Unknown 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL Sintilimab - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Qian Wenbin | 51 | 2020-12-10 | 2020-12-09 |
| R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Academic and Community Cancer Research United | 30 | 2016-05-20 | 2024-07-01 |
Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, B-Cell (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma, B-Cell (1)
CT-P10 (1) · Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Lenalidomide (1) · Rituximab (1) · sintilimab (1)
Academic and Community Cancer Research United (1) · Qian Wenbin (1)
China (1) · United States (1)
P30CA015083 (1)